Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.
复制标题
DOI：
10.1155/2015/158038
复制
发表时间：
2015
影响因子：
4.1
通讯作者：
Deschoolmeester V
中科院分区：
文献类型：
--
作者：
Jacobs J;Smits E;Lardon F;Pauwels P;Deschoolmeester V
结直肠癌（CRC）是世界范围内最常见的癌症之一，仍然是癌症相关死亡的主要原因。迫切需要更有效的治疗转移性疾病的方法。免疫疗法是一个迅速发展的肿瘤学领域，旨在增强人体的天然防御能力以对抗癌症。在目前正在研究的许多改善抗肿瘤免疫应答的方法中，免疫检查点抑制迄今已被证明是最有效的。这篇综述将概述利用我们对免疫系统在癌症中的作用的日益了解的治疗方法，特别强调参与CRC发病机制的免疫检查点分子。
Colorectal cancer (CRC), as one of the most prevalent types of cancer worldwide, is still a leading cause of cancer related mortality. There is an urgent need for more efficient therapies in metastatic disease. Immunotherapy, a rapidly expanding field of oncology, is designed to boost the body's natural defenses to fight cancer. Of the many approaches currently under study to improve antitumor immune responses, immune checkpoint inhibition has thus far been proven to be the most effective. This review will outline the treatments that take advantage of our growing understanding of the role of the immune system in cancer, with a particular emphasis on immune checkpoint molecules, involved in CRC pathogenesis.